Please login to the form below

Not currently logged in
Email:
Password:

defibrotide

This page shows the latest defibrotide news and features for those working in and with pharma, biotech and healthcare.

Jazz Pharma bags FDA approval for rare disease drug

Jazz Pharma bags FDA approval for rare disease drug

The US regulator has approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) as a complication of a haematological stem cell transplant (HSCT).

Latest news

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz Pharmaceuticals' Defitelio (defibrotide) for liver disease, GSK's respiratory combination Relvar Ellipta (fluticasone furoate / vilanterol)

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    The $57 per share deal gives Jazz an immediate boost in its ex-US business as well as access to Gentium's Defitelio (defibrotide) drug for the treatment of severe hepatic

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    Gentium is expecting the European Medicines Agency (EMA) to turn down its investigational medicine defibrotide for a liver condition associated with stem cell transplantation. ... Dr Khalid Islam, president and CEO of Gentium, said the company was

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US)    . 250. ArmaGen/ Shire   . Licence, collaboration   . AGT-182, enzyme replacement therapy for Hunter

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics